Literature DB >> 2827156

Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor.

S H Socher1, M W Riemen, D Martinez, A Friedman, J Tai, J C Quintero, V Garsky, A Oliff.   

Abstract

Human tumor necrosis factor (hTNF) mediates a variety of biologic activities, which are dependent on the attachment of hTNF to cell-surface receptors. To identify regions of the hTNF protein involved in binding hTNF to its receptor, we prepared five synthetic peptides [hTNF-(1-15), hTNF-(1-31), hTNF-(65-79), hTNF-(98-111), and hTNF-(124-141)] and two hydroxylamine cleavage fragments [hTNF-(1-39) and hTNF-(40-157)] of hTNF. The hTNF-synthetic peptides and hTNF fragments were tested in hTNF receptor binding assays and in two biologic assays: cytolysis of tumor cells and suppression of lipoprotein lipase in adipocytes. Neither the synthetic peptides nor hTNF fragments were active agonists or antagonists in these assays. The synthetic peptides were also conjugated to thyroglobulin, and peptide-specific antisera were raised. All five peptide-thyroglobulin conjugates induced antibody responses to the immunizing peptide and to hTNF. Each antiserum was tested for antagonist activity in hTNF binding assays. Only antisera raised against hTNF-(1-15) or hTNF-(1-31) and antisera against whole hTNF blocked binding. IgGs purified from these three antisera also block hTNF-induced cytolysis and lipoprotein lipase suppression. We conclude that antibodies that recognize the N-terminus of hTNF block the attachment of hTNF to its cellular receptor and inhibit the biologic effects of hTNF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2827156      PMCID: PMC299644          DOI: 10.1073/pnas.84.24.8829

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  Prediction of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Biochemistry       Date:  1974-01-15       Impact factor: 3.162

3.  Prediction of protein antigenic determinants from amino acid sequences.

Authors:  T P Hopp; K R Woods
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

4.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  Use of glutaraldehyde as a coupling agent for proteins and peptides.

Authors:  M Reichlin
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

Review 6.  Post-translational proteolysis in polypeptide hormone biosynthesis.

Authors:  K Docherty; D F Steiner
Journal:  Annu Rev Physiol       Date:  1982       Impact factor: 19.318

7.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

8.  A gas-liquid solid phase peptide and protein sequenator.

Authors:  R M Hewick; M W Hunkapiller; L E Hood; W J Dreyer
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

9.  Rabbit tumor necrosis factor: mechanism of action.

Authors:  M R Ruff; G E Gifford
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

10.  Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells.

Authors:  M Kawakami; P H Pekala; M D Lane; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

View more
  9 in total

1.  Production of polyclonal antibodies to feline tumor necrosis factor.

Authors:  C M Otto; F Niagro; R A McGraw; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping.

Authors:  P N Redlich; P D Hoeprich; C B Colby; S E Grossberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

3.  Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis.

Authors:  X Van Ostade; J Tavernier; T Prangé; W Fiers
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

4.  Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice.

Authors:  S H Socher; A Friedman; D Martinez
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

Review 5.  Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses.

Authors:  B Sherry; A Cerami
Journal:  J Cell Biol       Date:  1988-10       Impact factor: 10.539

6.  Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα.

Authors:  W Mark Abbott; Melanie Snow; Sonia Eckersley; Jonathan Renshaw; Gareth Davies; Richard A Norman; Peter Ceuppens; Jerry Slootstra; Joris J Benschop; Yoshitomo Hamuro; Jessica E Lee; Peter Newham
Journal:  Biosci Rep       Date:  2013-08-23       Impact factor: 3.840

7.  Expression of the functional soluble form of human fas ligand in activated lymphocytes.

Authors:  M Tanaka; T Suda; T Takahashi; S Nagata
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

8.  The effect of tumour necrosis factor-alpha (TNF-alpha) muteins on human neutrophils in vitro.

Authors:  H Tchorzewski; K Zeman; J Kantorski; E Paleolog; M Kahan; M Feldmann; M Kwinkowski; P Guga; B Szymanska; P Parniewski; A Wilk; J Jarosz
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

9.  A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor-alpha and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice.

Authors:  K Warzocha; J Góra-Tybor; M Kwinkowski; B Szymańska; T Robak
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.